他汀类药物抗骨质疏松作用的实验研究进展  

Experimental research progress on the anti-osteoporosis effects of statins

作　　者：项力源[1] 田发明[2] 刘会仁[1] 胡克俭[1] 刘家寅[2] 

机构地区：[1]唐山市第二医院,河北063000 [2]河北联合大学

出　　处：《中国骨与关节杂志》2015年第5期419-422,共4页Chinese Journal of Bone and Joint

摘　　要：他汀类药物是3-羟基-3-甲基戊二酰辅酶A（3-hydroxy-3-methylglutaryl-coenzyme A,HMG-Co A）还原酶抑制剂,通过抑制胆固醇合成链中的限速酶HMG-Co A还原酶,来减少胆固醇的合成[1]。1999年Mundy等[1]首次发现,他汀类药物有激活成骨细胞、促进骨合成代谢的作用。随后有研究者发现,辛伐他汀能在体内和体外环境下通过提升骨形态发生蛋白（bone morphogenetic protein，BMP）2和碱性磷酸酶（alkaline phosphatase，ALP）的表达水平刺激骨形成，还可以刺激骨髓间充质干细胞（bone marrow mesenchyme stromal cells，BMSCs）向成骨细胞分化[2-3]。Statins are 3-hydroxy-3-methylglutaryl coenzyme A （ HMG-CoA ） reductase inhibitors, which inhibit the endogenous synthesis of cholesterol. Recent studies have shown that statins can promote the proliferation of osteoblasts and bone formation and increase the mRNA level in bone morphogenetic protein 2 （ BMP2 ） in vitro. The literatures relevant to the experimental research on statins for the prevention and treatment of osteoporosis are summarized and analyzed in the paper, and the mechanism of anti-osteoporosis and application prospects of statins are briefly reviewed.

关 键 词：骨质疏松 药物疗法 药物载体 剂量效应关系 药物 

分 类 号：R965[医药卫生—药理学]